Agenda
London, 5 - 6 October 2021
Schedule
Create your personal agenda –check the favourite icon
Oct 510:00
Conference pass
Welcome Address
Keynotes
Jessica Robinson, Project director, Terrapinn Ltd
Oct 510:05
Conference pass
Cell-based COVID-19 vaccine and cancer vaccine update
Keynotes
Oct 510:25
Conference pass
Panel discussion: Learnings from the COVID outbreak and how to move forward into a brighter 2022
Keynotes
Consequences of COVID19 on the advanced therapies industry·Short term, reactive:oclinical trials and supply chainoImpact on businesses: need to resolve impact on finances and stock·Learnings, long term positive effects:oTechnology advancesoRegulatoryoEventsoGM organisations & legislation regulators lifted·What can we implement as a positive consequence?·Culture/evolutions of companies, how is working from home effecting how we work?
Miguel Forte, Chief Executive Officer, Bone Therapeutics
Amir Hefni, VP, Global Commercial Head, Cell & Gene, Novartis
Oct 511:00
Conference pass
Tackling large-scale, commercial regulatory challenges
Track 1: Commercialisation
Yemisi Corinaldi, Regulatory Strategy Leader, Spark Therapeutics UK Limited
Janet Glassford, Senior Quality Assessor, Medicines & Healthcare Products Regulatory Agency
Oct 514:00
Conference pass
Panel discussion: Evidence, pricing & market access
Track 1: Commercialisation
Amir Hefni, VP, Global Commercial Head, Cell & Gene, Novartis
Mike Fraser, Head of EMEA Region, Novartis Gene Therapies
Tamir Singer, Head of Commercial Development, NHS England
Oct 514:00
Conference pass
Precision medicine informed immuno-oncology
Track 2: Developing therapeutic modalities
Oct 514:00
Conference pass
Cell therapy manufacturing
Track 3: Manufacture & bioprocess
Oct 514:30
Conference pass
Base editing – An innovative and safer gene editing solution for advanced C>
Track 2: Developing therapeutic modalities
- Gene editing technologies have successfully been used to improve the next generation of C>.- However, standard gene editing platforms such as TALEN and CRISPR-Cas9 trigger concerning off target effects that could hinder wider clinical application.- Pin-point™ base editing offers more precise, efficacious and safer gene editing for innovative development of more potent and cost-effective C>.
Oct 514:30
Conference pass
Effective process development and keeping costs low
Track 3: Manufacture & bioprocess
Frank Barry, Scientific Director, Regenerative Medicine Institute
Paul S Carter, Director, Head Vector Processing, Quell Therapeutics
Oct 515:00
Conference pass
Regulatory session for academic and early-stage companies
Track 1: Commercialisation
·How and when small companies should apply for the EMA's Priority of medicines scheme (PRIME) and the FDA's Regenerative medicine advanced therapy designation (RMAT)
Victoria English, Victoria English, Co-Founder And Editor, Evernow Publications
Margareth Jorvid, Head of Regulatory Affairs, Ilya Pharma
Nneka Onwudiwe, Former PRO/PE Regulatory Review Officer, Food and Drug Administration (FDA)
Didier Caizergues, Head of International Regulatory Affairs, Genethon
Vicki Coutinho, VP Regulatory Affairs, GammaDelta Therapeutics
Tim Bertram, Chief Executive Officer, ProKidney
Oct 515:00
Conference pass
Tackling solid tumours: how do we move forward?
Track 2: Developing therapeutic modalities
Sven Kili, CEO, Antion Biosciences
Oct 515:00
Conference pass
Scaling up manufacture to a commercial level
Track 3: Manufacture & bioprocess
Sponsored by Oxford Biomedica
Volker Huppert, Chief Development Officer, Glycostem Therapeutics BV
Oct 515:30
Conference pass
Autologous vs Allogeneic: What’s next?
Track 2: Developing therapeutic modalities
- Will autologous therapies diminish in importance as genome editing gathers pace, making way for more allogeneic treatments?
Stefanos Theoharis, Chief Business Officer, Bone Therapeutics
Stewart Abbot, Chief Scientific Officer, Adicet Bio
Sven Kili, CEO, Antion Biosciences
Oct 515:30
Conference pass
A decade of experience in commercial cell therapy manufacturing, and lessons learned
Track 3: Manufacture & bioprocess
·Development of potency assay·Sharing insights to establish robust, reliable supply chain infrastructure for commercial scale·Optimizing manufacturing, supply chain, and logistics
Oct 516:30
Conference pass
Real world evidence
Track 1: Commercialisation
Paolo Morgese, EU Director Market Access & Member Relations, Alliance for Regenerative Medicine
Oct 516:30
Conference pass
Harnessing cell death for regenerative medicine
Track 2: Developing therapeutic modalities
Francesco Dazzi, Professor Of Regenerative And Hematological Medicine, King's College London
Oct 516:30
Conference pass
Closed systems and automated manufacture
Track 3: Manufacture & bioprocess
Mary Murphy, Principle Investigator, Remedi National University of Ireland Galway
Lilian Jallow, Research Coordinator, Karolinska Institutet
Oct 516:45
Conference pass
Cell-based Therapies and the Treatment of Chronic Kidney Disease: Phase II Interim Analysis of Autologous Cell Therapy for Diabetic Kidney Disease
Track 2: Developing therapeutic modalities
Oct 517:00
Conference pass
The science and business strategies surrounding our gamma/delta T cell programs
Track 1: Commercialisation
Oct 517:00
Conference pass
Stem cells and the secretome
Track 2: Developing therapeutic modalities
Nada Alaaeddine, Head Of The Regenerative And Inflammation Lab In The Faculty Of Medicine, Lebanese university
Oct 517:00
Conference pass
Application of a novel bioreactor system for automated expansion of adipose-derived mesenchymal stem cells under GMP-compliant conditions
Track 3: Manufacture & bioprocess
- The current implementation and deployment of autologous cell therapies remains a true challenge, mainly because of therapy manufacturing and cost-related issues
- The utilization of automated technologies for cell therapy manufacturing can make these processes more consistent, scalable and cost-effective
- This validation study shows how the NANT 001 System has demonstrated to be a useful tool for the automated GMP-compliant production of autologous adipose-derived MSCs
Frank Barry, Scientific Director, Regenerative Medicine Institute
Oct 517:15
Conference pass
Safety and proof of Concept data of a new allogenic cell therapy for treatment of orthopaedic disorders
Track 2: Developing therapeutic modalities
Oct 517:30
Conference pass
Caladrius Biosciences; Progress, challenges and learnings during the COVID-19 pandemic
Track 1: Commercialisation
Oct 517:30
Conference pass
Panel dicussion: Stem cells and regenerative medicine
Track 2: Developing therapeutic modalities
Sven Kili, CEO, Antion Biosciences
Derek Dashti, Founder And Chief Executive Officer, D and P Bioinnovations
Francesco Dazzi, Professor Of Regenerative And Hematological Medicine, King's College London
Oct 517:30
Conference pass
Learning from the evolution of the mAbs industry: a solution to impact and facilitate gene therapy manufacturing
Track 3: Manufacture & bioprocess
·Integration of an intensified and continuous process within an automated platform·Experimental results demonstrating the benefits of fixed-bed technology for gene therapy manufacturing
Martina Sebastian, Sales Manager, Univercells Technologies
Create your personal agenda –check the favourite icon
Oct 609:00
Conference pass
Panel discussion: Deals and investments made: what have we learnt and where are we going in 2022?
Keynotes
Vivienne Parry, Head Of Engagement, Genomics England
Dominic Schmidt, Partner, Syncona Investment Management Ltd
David Greenwald, Vice President Of Business Development, Deerfield Management
Owen Smith, Investment Director, 4BIO Capital
Oct 609:45
Conference pass
Keynote panel discussion: Broadening the scope of gene therapies, expanding towards less rare conditions
Keynotes
Janneke Meulenberg, Managing Director, MeiraGTx Netherlands B.V.
Paul Gissen, Professor of Metabolic Medicine, Head of Genetics and Genomic Medicine Department, UCL Great Ormond Street Institute of Child Health
Birgitte Volck, Non Executive Director, Soleno Therapeutics
Bobby Gaspar, CEO, Orchard Therapeutics
Oct 611:30
Conference pass
Workshop 2: New Data from the Cell and Gene Therapy Catapult shows Improved Yield & Quality for AAV Manufacturing Using Osmolality
Keynotes
- The importance of including osmolality as a critical process parameter within cell and gene therapy processes.
- Insight into new data looking at improved yield, quality and efficiency of AAVs using osmolality.
- A hands-on demonstration of Advanced Instrument’s latest osmometer
Oct 613:30
Conference pass
Panel discussion: Ask the investors
Track 1: Commercialisation
Sven Kili, CEO, Antion Biosciences
David Greenwald, Vice President Of Business Development, Deerfield Management
Owen Smith, Investment Director, 4BIO Capital
Oct 613:30
Conference pass
Lumevoq Gene Therapy in Leber Hereditary Optic Neuropathy (LHON)
Track 2: Developing therapeutic modalities
Oct 613:30
Conference pass
What’s next for patient delivery in 2022?
Track 3: Manufacture & bioprocess
Stefano Zancan, Head Clinical Development And Operations, Fondazione Telethon
Oct 613:45
Conference pass
Update on HIV gene therapy clinical trial
Track 2: Developing therapeutic modalities
Oct 614:00
Conference pass
Commercialisation: scaling up your business
Track 1: Commercialisation
Oct 614:00
Conference pass
Panel: Immunogenicity for gene therapy
Track 2: Developing therapeutic modalities
Key unresolved clinical issues in gene therapy: immunosuppression, re-dosing, and in-utero dosing
Paolo Morgese, EU Director Market Access & Member Relations, Alliance for Regenerative Medicine
Paul Gissen, Professor of Metabolic Medicine, Head of Genetics and Genomic Medicine Department, UCL Great Ormond Street Institute of Child Health
Oct 614:00
Conference pass
Patient delivery including logistics, transportation & distribution
Track 3: Manufacture & bioprocess
Oct 614:30
Conference pass
Business Development: collaboration and competition
Track 1: Commercialisation
Sven Kili, CEO, Antion Biosciences
Oct 614:30
Conference pass
Analytical tools to help the production of your gene therapy products
Track 2: Developing therapeutic modalities
Oct 614:30
Conference pass
Upcoming data management transitions and their impact on advanced therapy supply chains
Track 3: Manufacture & bioprocess
·The current challenges related to data management in conjunction with supply chain distribution.·Upcoming communication technology changes that will impact critical chain of custody, chain of condition and Chain of Compliance® data collection and management.·Next generation technologies associated with more effective management of chain of custody and chain of condition in the field.
Oct 615:00
Conference pass
Rare disease & orphan drugs: updates and discussion
Track 2: Developing therapeutic modalities
Paolo Morgese, EU Director Market Access & Member Relations, Alliance for Regenerative Medicine
Bobby Gaspar, CEO, Orchard Therapeutics
Frederic Chereau, Chief Executive Officer, LogicBio Therapeutics
Oct 615:00
Conference pass
UCL Therapeutic Innovation Networks (TINs) - Aims and opportunities
Track 2: Developing therapeutic modalities
Oct 615:00
Conference pass
Consolidated GMP Technology can help in Successful Fast Go-To-Market of New Advanced Cell Therapy Procedures
Track 3: Manufacture & bioprocess
- Rapid evolving scenario suggests a fast, flawless go-to-market for Advanced Therapies
- To address the above, a fast and reliable way to manage the different variables influencing Product and Process Quality, in the peculiar aspects of both, is required.
- Current closed technologies, integrated with suitable SOPs, can offer the right level of confidence for running AT processes solving the major production issues concerned with potential manufacturing failures, thus allowing early stable results and easier market access.
Oct 616:00
Conference pass
Precise and Efficient Non-viral CRISPR Gene Editing Solutions for T Cell Engineering
Track 2: Developing therapeutic modalities
- The overall advantage of non-viral CRISPR gene-editing method on T cell engineering compares to lentivirus transduction
- How to achieve high engineering efficiency and high cell viability via dedicated CRISPR reagents, with minimized off-target risk
- An overview of GenScript CRISPR portfolio
Lumeng Ye, Senior Scientist, R&D department, GenScript
Oct 616:00
Conference pass
Establishing the safety and efficacy of advanced therapies – the bio-distribution question
Track 3: Manufacture & bioprocess
·ATMPs bring a great opportunity for novel solutions for longstanding healthcare challenges – but with novel new therapies consideration is needed of the associated risks, which bring greater chances of newer and unique adverse events that are difficult to identify.·Current non-clinical and pre-clinical methods to understand ATMPS provide specificity to unique cell and gene therapies, but can often lack the tissue context, which is essential in understanding, delivery, bio-distribution and immune interactions.·How is RNAscope technology being used to expand understanding and answer important questions in the pre-clinical development of a range of advanced therapies
Oct 616:29
Conference pass
Cord Blood
Track 2: Developing therapeutic modalities
Oct 616:30
Conference pass
Phase II study results in treatment of diabetes type-1 with MSC from umbilical cord tissue
Track 2: Developing therapeutic modalities
Mathias Svahn, Chief Executive Officer, NextCell Pharma
Oct 616:30
Conference pass
Viral vector analytics and safe manufacture
Track 3: Manufacture & bioprocess
Oct 617:00
Conference pass
Cord blood advancements
Track 2: Developing therapeutic modalities
Mathias Svahn, Chief Executive Officer, NextCell Pharma
Oct 617:00
Conference pass
The latest advances on a monitoring system integrated bioreactor for 3D cell culture
Track 3: Manufacture & bioprocess
last published: 18/Sep/21 11:05 GMT
Organiser
